Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma

Cancer

Volumn 77, Issue 6, 1996, Pages 1149-1153

  Wos, Edward ^a   Olencki, Thomas ^a   Tuason, Laurie ^a   Budd, G Thomas ^a   Peereboom, David ^a   Sandstrom, Kate ^a   McLain, Denise ^a   Finke, James ^a   Bukowski, Ronald M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

GM CSF; metastatic; Phase II; renal cell carcinoma

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; ERYTHEMA; FEMALE; FEVER; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; KIDNEY CARCINOMA; LEUKOCYTOSIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOSIS; TUMOR REGRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 0029916070     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960315)77:6<1149::AID-CNCR22>3.0.CO;2-0     Document Type: Article

References (31)

1. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors. Biology and clinical applications. N Engl J Med 1989;321:1449-59.
2. Metcalf D, Begley CG, Johnson GR, Nicola NA, Vadas MA, Lopez AF, et al. Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1986;67:37-45.
3. Hesketh PJ, Sullivan R, Valeri CR, McCarroll LA. The production of granulocyte-monocyte colony-stimulating activity by isolated human T lymphocyte subpopulations. Blood 1984;63:1141-6.
4. Oster W, Lindemann A, Mertelsmann R, Herrmann F. Production of macrophage-, granulocyte-, granulocyte-macrophage-, and multi-colony-stimulating factor by peripheral blood cells. Eur J Immunol 1989;19:543-7.
5. Zsebo KM, Yuschenkoff VN, Schiffer S, Chang D, McCall E, Dinarello CA, et al. Vascular endothelial cells and granulopoiesis: Interleukin-1 stimulates release of G-CSF and GM-CSF. Blood 1988;71:99-103.
6. Wodnar-Filipowicz A, Heusser CH, Moroni C. Production of the hematopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature 1989;339:150-2.
7. Zucali JR, Dinarello CA, Oblon DJ, Gross MA, Anderson L, Weiner RS. Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. J Clin Invest 1986;77:1857-63.
8. Cantrell MA, Anderson D, Cerretti DP, Price V, McKereghan K, Tushinski RJ, et al. Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor. Proc Natl Acad Sci USA 1985;82:6250-4.
9. Herrmann F, Schulz G, Lindemann A, Meyenburg W, Oster W, Krumwieh D, et al. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1989;7:159-67.
10. Lieschke GJ, Maher D, O'Connor M, Green M, Sheridan W, Rallings M, et al. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration. Cancer Res 1990;50:606-14.
11. Bukowski RM, Murthy S, McLain D, Finke J, Andresen S, Tubbs R, et al. Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: Clinical and immunologic effects. J Immunother 1993;13:267-74.
12. Sisson SD, Dinarello CA. Production of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood 1988;72:1368-74.
13. Thomassen MJ, Ahmad M, Barna BP, Antal J, Wiedemann HP, Meeker DP, Klein J, et al. Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granulocyte-macrophage colony-stimulating factor therapy. Cancer Res 1991;51:857-62.
14. Reed SG, Nathan CF, Phil DL, Rodricks P, Shanebeck K, Conlon PJ, et al. Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma. J Exp Med 1987;166:1734-46.
15. Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986;232:506-8.
16. Foulke RS, Marshall MH, Trotta P, Von Hoff DD. In vitro assessment of the effects of granulocyte-macrophage colony stimulating factor on primary human tumors and derived lines. Cancer Res 1990;50:6264-7.
17. Cannistra SA, Rambaldi A, Spriggs DR, Herrmann F, Kufe D, Griffin JD. Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal monocytes. J Clin Invest 1987;79:1720-8.
18. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90:3539-43.
19. Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU. Antitumor activity of recombinant-derived Interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 1985;3: 1522-8.
20. Bukowski RM, Goodman P, Crawford ED, Sergi JS, Redman BG, Whitehead RP. Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: A Southwest Oncology Group study. J Natl Cancer Inst 1990;82:143-4.
21. Budd GT, Murthy S, Finke J, Sergi J, Gibson V, Medendorp S, et al. Phase I trial of high dose bolus interleukin-2 and interferon alpha-2a in patients with metastatic malignancy. J Clin Oncol 1992;10:804-9.
22. de Forges A, Rey A, Klink M, Ghosn M, Kramar A, Droz JP. Prognostic factors of adult metastatic renal carcinoma: A multivariate analysis. Semin Surg Oncol 1988;4:149-54.
23. Devereux S, Bull HA, Campos-Costa D, Saib R, Linch DC. Granulocyte macrophage colony stimulating factor induced changes in cellular adhesion molecule expression and adhesion to endothelium: In-vitro and in-vivo studies in man. Br J Haematol 1989;71:323-30.
24. Steward WP, Scarffe JH, Austin R, Bonnem E, Thatcher N, Morgenstern G, et al. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions - A Phase I dose-toxicity study. Br J Cancer 1989;59:142-5.
25. O'Donnell RT, Dea G, Meyers FJ. A Phase II trial of concomitant interferon-alpha-2b and granulocyte macrophage colony-stimulating factor in patients with advanced renal cell cancer. J Immunother 1995;17:58-61.
26. Edmonson JH, Long HJ, Kvols LK. Cytotoxic drugs plus subcutaneous granulocyte-macrophage colony stimulating factor: Can molgramostim enhance antisarcoma therapy. J Natl Cancer Inst 1994;86:312.
27. Golumbek PT, Azhari R, Jaffee EM, Levitsky HI, Lazenby A, Leong K, et al. Controlled release, biodegradable cytokine depots: A new approach in cancer vaccine design. Cancer Res 1993;53:5841-4.
28. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264: 961-5.
29. Oliver RT, Miller RMM, Mehta A, Barnett MJ. A Phase II study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression. Mol Biother 1988;1:14-20.
30. Montie JE, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977;117:272-5.
31. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony stimulating factor. J Exp Med 1992;176:1693-702.